| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2013 ( Subtotal = $864,478 ) |
| | 2013 | 2013 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R44AI080030 | PRECLINICAL DEVELOPMENT OF A NOVEL AND POWERFUL IMMUNOTHERAPEUTIC | 000 | 4 | NIH | 1/10/2013 | $864,478 |
|
| Issue Date FY: 2012 ( Subtotal = $1,147,617 ) |
| | 2012 | 2012 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI098261 | SAFE AND EFFECTIVE ANTI CD154 ANTIBODIES FOR THERAPEUTIC INTERVENTION | 000 | 1 | NIH | 3/1/2012 | $300,000 |
| | 2012 | 2012 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R44AI080030 | PRECLINICAL DEVELOPMENT OF A NOVEL AND POWERFUL IMMUNOTHERAPEUTIC | 000 | 3 | NIH | 2/3/2012 | $847,617 |
|
| Issue Date FY: 2011 ( Subtotal = $1,464,436 ) |
| | 2011 | 2011 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI096682 | VISTA: A NOVEL THERAPEUTIC TARGET THAT NEGATIVELY REGULATES IMMUNITY | 000 | 1 | NIH | 8/2/2011 | $300,000 |
| | 2011 | 2011 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI088948 | ANGIOGENESIS ANTAGONIST PLUS CD40-TLR AGONIST ADJUVANT COMBINATION VACCINE | 000 | 2 | NIH | 3/14/2011 | $237,514 |
| | 2011 | 2011 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R44AI080030 | PRECLINICAL DEVELOPMENT OF A NOVEL AND POWERFUL IMMUNOTHERAPEUTIC | 000 | 2 | NIH | 1/15/2011 | $926,922 |
|
| Issue Date FY: 2010 ( Subtotal = $607,280 ) |
| | 2010 | 2010 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI088948 | ANGIOGENESIS ANTAGONIST PLUS CD40-TLR AGONIST ADJUVANT COMBINATION VACCINE | 001 | 1 | NIH | 9/2/2010 | $0 |
| | 2010 | 2010 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI088948 | ANGIOGENESIS ANTAGONIST PLUS CD40-TLR AGONIST ADJUVANT COMBINATION VACCINE | 000 | 1 | NIH | 3/30/2010 | $300,000 |
| | 2010 | 2010 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI077229 | POTENT VACCINE ADJUVANT THERAPEUTIC | 002 | 2 | NIH | 8/25/2010 | $277,222 |
| | 2010 | 2010 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI088948 | ANGIOGENESIS ANTAGONIST PLUS CD40-TLR AGONIST ADJUVANT COMBINATION VACCINE | 002 | 1 | NIH | 9/13/2010 | $0 |
| | 2010 | 2009 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI077229 | POTENT VACCINE ADJUVANT THERAPEUTIC | 001 | 1 | NIH | 1/1/2010 | $30,058 |
| | 2010 | 2009 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI077229 | POTENT VACCINE ADJUVANT THERAPEUTIC | 000 | 1 | NIH | 1/1/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $629,936 ) |
| | 2009 | 2009 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI080030 | CREATION OF AN ANTI-CD40 SUPERAGONISTIC MONOCLONAL ANTIBODY | 000 | 1 | NIH | 4/17/2009 | $329,936 |
| | 2009 | 2009 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI077229 | POTENT VACCINE ADJUVANT THERAPEUTIC | 000 | 1 | NIH | 8/27/2009 | $269,942 |
| | 2009 | 2009 | IMMURX INC | 10 WATER STREET | LEBANON | NH | 03766 | GRAFTON | USA | R43AI077229 | POTENT VACCINE ADJUVANT THERAPEUTIC | 001 | 1 | NIH | 9/7/2009 | $30,058 |
|
|
